These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204 [TBL] [Abstract][Full Text] [Related]
3. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571 [TBL] [Abstract][Full Text] [Related]
4. Depot bromperidol decanoate for schizophrenia. Wong D; Adams CE; David A; Quraishi SN Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450 [TBL] [Abstract][Full Text] [Related]
5. Bromperidol decanoate (depot) for schizophrenia. Purgato M; Adams CE Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678 [TBL] [Abstract][Full Text] [Related]
6. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Nyberg S; Farde L; Halldin C Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776 [TBL] [Abstract][Full Text] [Related]
7. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. Kane JM J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088 [TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of the depot antipsychotics. Jann MW; Ereshefsky L; Saklad SR Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156 [TBL] [Abstract][Full Text] [Related]
9. A loading-dose strategy for converting from oral to depot haloperidol. Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570 [TBL] [Abstract][Full Text] [Related]
10. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Olfson M; Marcus SC; Ascher-Svanum H Schizophr Bull; 2007 Nov; 33(6):1379-87. PubMed ID: 17470444 [TBL] [Abstract][Full Text] [Related]
11. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. arap Mengech HN; Wazome EG East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736 [No Abstract] [Full Text] [Related]
12. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463 [TBL] [Abstract][Full Text] [Related]
13. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Suzuki H; Gen K Hum Psychopharmacol; 2012 Sep; 27(5):470-5. PubMed ID: 23001955 [TBL] [Abstract][Full Text] [Related]
14. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177 [TBL] [Abstract][Full Text] [Related]
16. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E Drugs; 2003; 63(5):493-512. PubMed ID: 12600227 [TBL] [Abstract][Full Text] [Related]
17. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Youssef HA Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308 [TBL] [Abstract][Full Text] [Related]
18. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307 [TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability study of two haloperidol decanoate containing products. van Weringh G; Komen BJ; Thieme RE; van der Hoeven RT; Vos T Pharm World Sci; 1994 Dec; 16(6):243-7. PubMed ID: 7889022 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of inpatient depot antipsychotic prescribing. Pabis DJ; Dorson PG; Crismon ML Ann Pharmacother; 1996 Dec; 30(12):1381-6. PubMed ID: 8968447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]